Watkin S W, Green J A
Cancer Research Campaign, University of Liverpool, England.
Acta Oncol. 1990;29(6):733-7. doi: 10.3109/02841869009092992.
Twenty-eight patients with non-Hodgkin's lymphomas considered unsuitable for doxorubicin containing combination chemotherapy were given the four-drug combination chlorambucil, mitoxantrone, procarbazine and prednisolone every 3 weeks. The median age of the patients was 69 years and 15 had received prior treatment. Non-haematological toxicity was WHO grade I or II in all cases. Five patients had grade 4 neutropenia of which 3 were associated with fever and one was fatal. The complete response rate was 32% and the overall response rate 61%. The actuarial survival of the 17 responding patients at 12 months was 68%. This outpatient regimen produced good compliance among elderly patients, and modest toxicity with acceptable response rate and survival for the study population.
28例被认为不适合接受含阿霉素联合化疗的非霍奇金淋巴瘤患者，每3周接受一次由苯丁酸氮芥、米托蒽醌、丙卡巴肼和泼尼松组成的四联化疗。患者的中位年龄为69岁，其中15例曾接受过先前治疗。所有病例的非血液学毒性均为世界卫生组织I级或II级。5例患者出现4级中性粒细胞减少，其中3例伴有发热，1例死亡。完全缓解率为32%，总缓解率为61%。17例缓解患者12个月时的精算生存率为68%。这种门诊治疗方案在老年患者中依从性良好，毒性适度，研究人群的缓解率和生存率可接受。
